Pricing Log in Create free account
Saturday 17 October 2026 Export HLN’s income statement to Excel — free account

Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.

10.13 0.19 +1.91%
Market cap
$43.7B
P/E
22.6×
Fwd P/E
17.6×
Dividend yield
1.95%
F-score
8/9
Altman Z
3.04
Beneish M
−2.60
Dividend safety
66/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 4.36%

Capital & Financial Ratios $m

Market Cap 43,710.00
Revenue 18,122.53
Net Income 3,070.88
Free Cash Flow 4,551.19
Net Debt 9,966.43
Current Ratio 0.69 (below 1: weak)
Debt/Equity 0.50
P/E ratio 22.58
Fwd P/E 17.60
P/S ratio 2.57
P/B ratio 2.11
Past 5Y EPS Growth 24.41% (at or above 15%: strong)
This Y EPS Growth 10.32%
Next Y EPS Growth 8.86%
Next Y revenue growth 3.03%
Next 5Y EPS Growth 9.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.1×, against a ten-year median of 3.1×; over the ten years it ranged from 2.7× in 2024 to 3.5× in 2025.
P/B against its own 10 years 69.66%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.20
Annual Dividend Yield 1.95%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.11
0.13
0.06
2025 0.10
0.12
0.06
2024 0.16
0.11
0.05
2023 0.10
0.06
0.04
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,299 2,875 1,746 1,109
Receivables 2,422 2,745 2,800 3,151
Inventory 1,751 1,521 1,352 1,437
Other 521 166 103 62
5,993 7,307 6,000 5,759
2023 2024 2025 Q'26
Payables 4,386 4,735 4,919 5,095
ST’ Debt 816 1,900 1,102 2,633
Other 211 492 132 297
5,772 7,427 6,505 8,380

Compound Annual Growth %

10y 5y 3y
Sales — 1.43% 2.69%
Cash Flow — 12.50% 10.83%
Earnings — 6.98% 18.80%
Book Value — (9.48%) 2.21%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 14,545
’24 3,702 — 3,616 — 14,355
’23 3,627 7,263 3,542 — 14,059
’22 — — — — 13,430
’21 — — — — 12,899
’20 — — — — 13,551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 3,473
’24 — — — — 2,940
’23 — — — — 2,612
’22 — — — — 2,552
’21 — — — — 1,834
’20 — — — — 1,927
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — 1,241 — — —
’25 — 1,199 — — 2,929
’24 — 1,339 — — 2,949
’23 — 771 — — 2,500
’22 — 757 — 2,176 2,191
’21 — — — — 1,834
’20 — — — — 1,927
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 0.49
’24 0.12 — 0.14 — 0.40
’23 0.10 0.09 0.10 — 0.28
’22 — — — — 0.28
’21 — — — — 0.20
’20 — — — — 0.16
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — 5.59 7.49 7.89 8.71

Analyst estimates 2026–2028

Powerpack
High — — — — — — 8.50 9.05 10.80 11.42
People
People Employees — — — — — 22,800 24,622 25,408 24,561 24,535
Revenue/emp, $m — — — 0.00 0.00 0.57 0.55 0.55 0.58 0.59
Income, $m
Income, $m Revenue — — — 11,158 13,551 12,899 13,430 14,059 14,355 14,545
Gross margin, % — — — 56.63 59.75 62.34 60.57 59.70 60.75 64.19
EBT — — — 1,166 2,179 2,211 2,001 2,025 2,441 2,838
EBT margin, % — — — 10.45 16.08 17.14 14.90 14.40 17.00 19.51
Net income — — — 862 1,568 0 1,384 1,382 1,885 2,215
Depreciation — — — 342 418 362 355 384 414 475
Per share, $
Per share, $ Revenue — — — 2.41 2.93 2.79 2.91 3.05 3.14 3.24
Earnings — — — 0.09 0.16 0.20 0.28 0.28 0.40 0.49
Cash flow — — — 0.22 0.42 0.40 0.55 0.57 0.64 0.77
Capex — — — 0.00 0.00 0.00 (0.08) (0.02) 0.00 (0.12)
Free cash flow — — — 0.22 0.42 0.40 0.47 0.54 0.65 0.65
Book value — — — 7.78 7.74 7.71 4.41 4.51 4.54 4.84
Shares, m — — — 4,621 4,621 4,621 4,618 4,617 4,566 4,491
Valuation, ×
Valuation, × P/E — — — 20.41 20.41 20.41 20.41 20.41 21.27 22.54
P/S — — — 0.00 0.00 0.00 0.00 0.00 2.42 2.57
P/B — — — 0.00 0.00 0.00 0.00 1.83 2.08 2.18
EV/Sales — — — 0.00 0.00 0.00 0.00 0.00 3.00 3.14
EV/FCF — — — 0.00 0.00 0.00 0.00 0.00 11.64 11.04
Cash, $m
Cash, $m Operating cash flow — — — 1,028 1,927 1,834 2,552 2,612 2,940 3,473
Capex — — — (320) (436) (403) (361) (112) 9 (545)
Free cash flow — — — 1,028 1,927 1,834 2,191 2,500 2,949 2,929
Balance, $m
Balance, $m Working capital — — — 2,029 1,362 1,369 (385) 221 (120) (505)
Total debt — — — 845 667 1,339 12,913 11,762 12,941 11,353
Net debt — — — 397 210 780 12,067 10,464 10,066 9,607
Shareholders’ equity — — — 35,949 35,770 35,615 20,356 20,809 20,733 21,737
Returns, %
Returns, % ROA — — — 0.00 3.35 8.04 2.92 3.06 4.27 5.06
ROIC — — — 0.00 0.00 0.00 4.35 4.96 5.72 6.34
ROE — — — 0.00 4.37 5.26 4.69 6.34 8.87 10.35
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2024

Charts ten years each

Haleon PLC Sponsored ADR vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TAK Takeda Pharmaceutical Co. $61.9B 29.6× — +1.71% (above 0%: growing) −4.35% (below 0%: shrinking) −95.56% (below 0%: shrinking) 66.66% 16.51% Compare
TEVA Teva Pharmaceutical Industries Ltd. $47.9B 65.9× 30.7× −0.81% (below 0%: shrinking) n/m +121.43% (above 0%: growing) 51.98% (2.03%) Compare
HLN Haleon PLC Sponsored ADR $43.7B 22.6× 17.6× −0.32% (below 0%: shrinking) +40.00% (above 0%: growing) −42.94% (below 0%: shrinking) 62.88% 25.36%
ZTS Zoetis Inc. $32.4B 13.0× 12.3× −0.24% (below 0%: shrinking) +2.48% (above 0%: growing) +17.43% (above 0%: growing) 72.73% 37.56% Compare
UTHR United Therapeutics Corporation $23.2B 17.6× 20.1× −1.92% (below 0%: shrinking) +13.99% (above 0%: growing) +58.76% (above 0%: growing) 87.30% 42.23% Compare
VTRS Viatris Inc. $20.9B — (loss-making) 61.1× +4.88% (above 0%: growing) n/m +101.08% (above 0%: growing) 38.77% 0.17% Compare
NBIX Neurocrine Biosciences, Inc. $13.9B 19.2× 30.5× +39.49% (above 0%: growing) +31.19% (above 0%: growing) +43.69% (above 0%: growing) 97.58% 15.80% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 278× +10.23% (above 0%: growing) +450.00% (above 0%: growing) +35.56% (above 0%: growing) 58.33% 7.97% Compare
RDY Dr. Reddy's Laboratories Ltd $10.7B 32.9× 24.3× −14.44% (below 0%: shrinking) −70.00% (below 0%: shrinking) −143.40% (below 0%: shrinking) 46.54% 4.81% Compare
Median of peers $22.1B 24.4× 30.5× +0.74% +8.23% +39.63% 62.50% 11.89%

All 86 Drug Manufacturers Specialty & Generic stocks →

Haleon PLC Sponsored ADR (HLN) key facts

  • Strength: Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
  • Haleon PLC Sponsored ADR (HLN) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, HLN traded at $10.13, a market capitalization of $43.7 billion.
  • Haleon PLC Sponsored ADR pays an annual dividend of $0.20 per share, a yield of 1.95%.
  • Return on equity was 10.4% and debt-to-equity 0.50.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.04 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Haleon PLC Sponsored ADR (HLN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/HLN · Data as of Sep 30, 2024 · For information only; not investment advice. · © 2026 stockrow.com